Logicbio Therapeutics Inc., of Cambridge, Mass., set a price range for its proposed IPO of 5.8 million shares at $12 to $14, which would raise $75.4 million at the midpoint. Insiders intend to purchase up to $30 million of the IPO. The preclinical-stage gene editing firm seeks to list on Nasdaq under the ticker LOGC. Jefferies, Barclays and William Blair are acting as joint bookrunners.